Compare SCD & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCD | XOMA |
|---|---|---|
| Founded | 2003 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.2M | 308.6M |
| IPO Year | N/A | N/A |
| Metric | SCD | XOMA |
|---|---|---|
| Price | $15.18 | $36.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $60.60 |
| AVG Volume (30 Days) | 37.3K | ★ 110.6K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 9.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.59 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.79 | $20.00 |
| 52 Week High | $16.89 | $39.92 |
| Indicator | SCD | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 84.22 |
| Support Level | $14.70 | $23.96 |
| Resistance Level | $15.86 | $39.46 |
| Average True Range (ATR) | 0.39 | 1.60 |
| MACD | 0.06 | 0.60 |
| Stochastic Oscillator | 62.77 | 98.15 |
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.